FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200318858> ?p ?o ?g. }

• W4200318858 endingPage "100142" @default.
• W4200318858 startingPage "100142" @default.
• W4200318858 abstract "Observational studies have postulated a therapeutic role of metformin in treating COVID-19. We conducted an adaptive platform clinical trial to determine whether metformin is an effective treatment for high-risk patients with early COVID-19 in an outpatient setting.The TOGETHER Trial is a placebo-controled, randomized, platform clinical trial conducted in Brazil. Eligible participants were symptomatic adults with a positive antigen test for SARS-CoV-2. We enroled eligible patients over the age of 50 years or with a known risk factor for disease severity. Patients were randomly assigned to receive either placebo or metformin (750 mg twice daily for 10 days or placebo, twice daily for 10 days). The primary outcome was hospitalization defined as either retention in a COVID-19 emergency setting for > 6 h or transfer to tertiary hospital due to COVID-19 at 28 days post randomization. Secondary outcomes included viral clearance at day 7, time to hospitalization, mortality, and adverse drug reactions. We used a Bayesian framework to determine probability of success of the intervention compared to placebo.The TOGETHER Trial was initiated June 2, 2020. We randomized patients to metformin starting January 15, 2021. On April 3, 2021, the Data and Safety Monitoring Committee recommended stopping enrollment into the metformin arm due to futility. We recruited 418 participants, 215 were randomized to the metformin arm and 203 to the placebo arm. More than half of participants (56.0%) were over the age of 50 years and 57.2% were female. Median age was 52 years. The proportion of patients with the primary outcome at 28 days was not different between the metformin and placebo group (relative risk [RR] 1.14[95% Credible Interval 0.73; 1.81]), probability of superiority 0.28. We found no significant differences between the metformin and placebo group on viral clearance through to day 7 (Odds ratio [OR], 0.99, 95% Confidence Intervals 0.88-1.11) or other secondary outcomes.In this randomized trial, metformin did not provide any clinical benefit to ambulatory patients with COVID-19 compared to placebo, with respect to reducing the need for retention in an emergency setting or hospitalization due to worsening COVID-19. There were also no differences between metformin and placebo observed for other secondary clinical outcomes." @default.
• W4200318858 created "2021-12-31" @default.
• W4200318858 creator A5003587330 @default.
• W4200318858 creator A5008692405 @default.
• W4200318858 creator A5012468553 @default.
• W4200318858 creator A5019897274 @default.
• W4200318858 creator A5022147563 @default.
• W4200318858 creator A5022908989 @default.
• W4200318858 creator A5029801001 @default.
• W4200318858 creator A5031717153 @default.
• W4200318858 creator A5033230288 @default.
• W4200318858 creator A5041903492 @default.
• W4200318858 creator A5042392599 @default.
• W4200318858 creator A5048125439 @default.
• W4200318858 creator A5049279040 @default.
• W4200318858 creator A5052226980 @default.
• W4200318858 creator A5054894404 @default.
• W4200318858 creator A5055834351 @default.
• W4200318858 creator A5067792222 @default.
• W4200318858 creator A5072642255 @default.
• W4200318858 creator A5074297778 @default.
• W4200318858 creator A5077592035 @default.
• W4200318858 creator A5079110860 @default.
• W4200318858 creator A5080318948 @default.
• W4200318858 creator A5088577254 @default.
• W4200318858 date "2022-02-01" @default.
• W4200318858 modified "2023-10-10" @default.
• W4200318858 title "Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial" @default.
• W4200318858 cites W2045278350 @default.
• W4200318858 cites W2262325221 @default.
• W4200318858 cites W2621191844 @default.
• W4200318858 cites W2740487349 @default.
• W4200318858 cites W3017796721 @default.
• W4200318858 cites W3026023260 @default.
• W4200318858 cites W3035123324 @default.
• W4200318858 cites W3072304586 @default.
• W4200318858 cites W3073804858 @default.
• W4200318858 cites W3092285140 @default.
• W4200318858 cites W3109186718 @default.
• W4200318858 cites W3156859932 @default.
• W4200318858 cites W3182188484 @default.
• W4200318858 doi "https://doi.org/10.1016/j.lana.2021.100142" @default.
• W4200318858 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34927127" @default.
• W4200318858 hasPublicationYear "2022" @default.
• W4200318858 type Work @default.
• W4200318858 citedByCount "20" @default.
• W4200318858 countsByYear W42003188582021 @default.
• W4200318858 countsByYear W42003188582022 @default.
• W4200318858 countsByYear W42003188582023 @default.
• W4200318858 crossrefType "journal-article" @default.
• W4200318858 hasAuthorship W4200318858A5003587330 @default.
• W4200318858 hasAuthorship W4200318858A5008692405 @default.
• W4200318858 hasAuthorship W4200318858A5012468553 @default.
• W4200318858 hasAuthorship W4200318858A5019897274 @default.
• W4200318858 hasAuthorship W4200318858A5022147563 @default.
• W4200318858 hasAuthorship W4200318858A5022908989 @default.
• W4200318858 hasAuthorship W4200318858A5029801001 @default.
• W4200318858 hasAuthorship W4200318858A5031717153 @default.
• W4200318858 hasAuthorship W4200318858A5033230288 @default.
• W4200318858 hasAuthorship W4200318858A5041903492 @default.
• W4200318858 hasAuthorship W4200318858A5042392599 @default.
• W4200318858 hasAuthorship W4200318858A5048125439 @default.
• W4200318858 hasAuthorship W4200318858A5049279040 @default.
• W4200318858 hasAuthorship W4200318858A5052226980 @default.
• W4200318858 hasAuthorship W4200318858A5054894404 @default.
• W4200318858 hasAuthorship W4200318858A5055834351 @default.
• W4200318858 hasAuthorship W4200318858A5067792222 @default.
• W4200318858 hasAuthorship W4200318858A5072642255 @default.
• W4200318858 hasAuthorship W4200318858A5074297778 @default.
• W4200318858 hasAuthorship W4200318858A5077592035 @default.
• W4200318858 hasAuthorship W4200318858A5079110860 @default.
• W4200318858 hasAuthorship W4200318858A5080318948 @default.
• W4200318858 hasAuthorship W4200318858A5088577254 @default.
• W4200318858 hasBestOaLocation W42003188581 @default.
• W4200318858 hasConcept C126322002 @default.
• W4200318858 hasConcept C142724271 @default.
• W4200318858 hasConcept C168563851 @default.
• W4200318858 hasConcept C194828623 @default.
• W4200318858 hasConcept C197934379 @default.
• W4200318858 hasConcept C202953159 @default.
• W4200318858 hasConcept C204243189 @default.
• W4200318858 hasConcept C204787440 @default.
• W4200318858 hasConcept C23131810 @default.
• W4200318858 hasConcept C27081682 @default.
• W4200318858 hasConcept C2779306644 @default.
• W4200318858 hasConcept C2780323712 @default.
• W4200318858 hasConcept C535046627 @default.
• W4200318858 hasConcept C71924100 @default.
• W4200318858 hasConceptScore W4200318858C126322002 @default.
• W4200318858 hasConceptScore W4200318858C142724271 @default.
• W4200318858 hasConceptScore W4200318858C168563851 @default.
• W4200318858 hasConceptScore W4200318858C194828623 @default.
• W4200318858 hasConceptScore W4200318858C197934379 @default.
• W4200318858 hasConceptScore W4200318858C202953159 @default.
• W4200318858 hasConceptScore W4200318858C204243189 @default.
• W4200318858 hasConceptScore W4200318858C204787440 @default.
• W4200318858 hasConceptScore W4200318858C23131810 @default.
• W4200318858 hasConceptScore W4200318858C27081682 @default.

• next